



To NASDAQ OMX Copenhagen A/S  
Investor News no. 01-14 / Copenhagen, January 23, 2014

**Topotarget A/S**  
Symbion  
Fruebjergvej 3  
DK-2100 Copenhagen  
Denmark  
Tel: +45 39 17 83 92  
Email address:  
enquiries@topotarget.com  
Comp. reg.: 25695771  
**www.topotarget.com**

## **Teleconference regarding interim report for the period January 1 – December 31, 2013**

**Topotarget will host a teleconference regarding the company's interim report for the period January 1 – December 31, 2013 on January 30, 2014 at 1:00 pm CET.**

CEO Anders Vadsholt will present the interim report for the period January 1 – December 31, 2013 and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget's website, [www.topotarget.com](http://www.topotarget.com), before the start of the conference call.

To participate in the conference call, please dial:

- Denmark: 32 72 80 18
- International: +44 (0) 1452 555131

Conference ID: 22225481#

You will be able to stream the telephone conference via the following link:

<http://www.media-server.com/m/p/zqvxbab7>

After the call, a playback will be available via the same link.

### **Topotarget A/S**

For further information, please contact:  
Anders Vadsholt, CEO – direct: +45 39178345

### **Background information**

#### **About Topotarget**

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

#### **Topotarget Safe Harbor Statement**

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.